MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles

Achraf Al Faraj¹
Asma Sultana Shaik¹
Sibtain Afzal²
Baraa Al Sayed¹
Rabih Halwani²
¹King Saud University, College of Applied Medical Sciences, Department of Radiological Sciences, Molecular and Cellular Imaging Lab, Riyadh, Saudi Arabia; ²King Saud University, Prince Naif Center for Immunology Research, Asthma Research Chair, College of Medicine, Riyadh, Saudi Arabia

Purpose: Targeting and noninvasive imaging of a specific alveolar macrophage subpopulation in the lung has revealed the importance for early and better diagnosis and therapy of chronic obstructive pulmonary disease (COPD). In this study, the in vivo effect of pulmonary administration of iron oxide nanoparticles on the polarization profile of macrophages was assessed, and a noninvasive free-breathing magnetic resonance imaging (MRI) protocol coupled with the use of biocompatible antibody-conjugated superparamagnetic iron oxide (SPIO) nanoparticles was developed to enable specific targeting and imaging of a particular macrophage subpopulation in lipopolysaccharide-induced COPD mice model.

Materials and methods: Enzyme-linked immunosorbent assay, Real-time polymerase chain reaction, and flow cytometry analysis were performed to assess the biocompatibility of PEGylated dextran-coated SPIO nanoparticles. Specific biomarkers for M1 and M2 macrophages subsets were selected for conjugation with magnetic nanoparticles. MRI protocol using ultra-short echo time sequence was optimized to enable simultaneous detection of inflammation progress in the lung and detection of macrophages subsets. Flow cytometry and immunohistochemistry analysis were finally performed to confirm MRI readouts and to characterize the polarization profile of targeted macrophages.

Results: The tested SPIO nanoparticles, under the current experimental conditions, were found to be biocompatible for lung administration in preclinical settings. Cluster of differentiation (CD)86- and CD206-conjugated magnetic nanoparticles enabled successful noninvasive detection of M1 and M2 macrophage subpopulations, respectively, and were found to co-localize with inflammatory regions induced by lipopolysaccharide challenge. No variation in the polarization profile of targeted macrophages was observed, even though a continuum switch in their polarization might occur. However, further confirmatory studies are required to conclusively establish this observation.

Conclusion: Coupling of magnetic iron oxide nanoparticles with a specific antibody targeted to a particular macrophage subpopulation could offer a promising strategy for an early and better diagnosis of pulmonary inflammatory diseases using noninvasive MRI.

Keywords: magnetic resonance imaging, MRI, lung imaging, lung inflammation, iron oxide nanoparticles, macrophage tracking, lipopolysaccharide

Introduction
Predicted to be the third leading cause of death, and the fifth leading cause of disability by 2020, chronic obstructive pulmonary disease (COPD) will certainly impose a greater burden on the health care system globally.¹ Therefore, new methodologies...
are required to better assess the pathological and physiological impairments of this progressive disease and to provide alternative diagnosis and therapies.

Studies in experimental animals and clinical settings have led to the concept that alveolar macrophages (AMs) play a central role in the pathogenesis of COPD as a major source of mediators. AMs are among the most abundant cells in the respiratory tract and are characterized by considerable diversity and plasticity in response to various signals within this environment. AMs undergo classical pro-inflammatory M1 activation, which is characterized by the expression of high levels of pro-inflammatory cytokines, high production of reactive nitrogen and oxygen intermediates, promotion of T helper-1 response, and strong tumoricidal and microbicidal activity. Alternatively, they may have an immunoregulatory M2 activation, which might be implicated in parasite containment and promotion of tissue remodeling and disease progression.

Although progress has been made to characterize the surface phenotype, activating signals and molecular pathways associated with different forms of macrophage activation, full delineation of this diversity under in vivo conditions requires further investigation. Therefore, imaging and targeting of specific AM subpopulation in COPD will be of great importance to understand the molecular events involved in its pathophysiology and/or help in early and better diagnosis.

Among the different strategies for inflammation imaging, molecularly targeted nanoparticles have been recognized as the most promising to achieve breakthroughs in health care. Magnetic nanoparticles possess much versatility that make them well suited for these applications by having the potential to enable early detection and prevention, and essentially improve diagnosis, treatment, and follow-up of diseases. They are widely utilized in translational cell- and animal-based experiments, and some of these nanomaterials are now US Food and Drug Administration (FDA) approved for human use.

Macrophage imaging using magnetic resonance imaging (MRI), coupled with the use of iron oxide magnetic nanoparticles, has emerged in recent times as a promising noninvasive technique for preclinical and clinical studies of several inflammatory diseases. This technique has been successfully used in different preclinical and clinical applications such as atherosclerosis and myocardial infarction, stroke, multiple sclerosis, rheumatoid arthritis, and kidney transplantation. However, limited investigations of inflammation and macrophage trafficking in the lung using imaging technologies has been performed because of the difficulties in imaging this organ (ie, signal loss due to cardiac pulsation and respiration, susceptibility artifacts caused by multiple air-tissue interfaces, and low proton density). With the ongoing technical improvements in gradient systems and development of MRI pulse sequence techniques, noninvasive detection using MRI may open new perspectives for imaging, diagnosis, and treatment of respiratory diseases such as COPD.

We have recently reported the possibility of noninvasive tracking of macrophage subsets in an inflammatory model using high resolution MRI after their intravenous administration. In addition, we have shown in another study that the ex vivo labeling of macrophage subpopulations with iron oxide nanoparticles did not affect their polarization and proliferation. It was proposed that coupling of iron oxide nanoparticles with a specific antibody targeted to a particular subpopulation of macrophages could offer a promising strategy for an early and better diagnosis of different inflammatory diseases using noninvasive MRI. Therefore, the purpose of the current study was to assess the in vivo effect of intrapulmonary administration of superparamagnetic iron oxide (SPIO) nanoparticles on AM polarization profiles in a COPD model and to develop a noninvasive MRI protocol to specifically target and monitor a macrophage subpopulation using specific antibody-conjugated SPIO nanoparticles.

**Material and methods**

**Animals and COPD model**

Female BALB/c mice (20–22 g) were obtained from the University’s main animal care center. All experiments were performed in accordance with the National guidelines for the care of laboratory animals, and the study was approved by the Ethical Committee of the College of Applied Medical Sciences (agreement number: CAMSO5/3334). COPD model was induced by intrapulmonary instillation (0.5 mg·kg⁻¹; volume [V] =100 µL) of lipopolysaccharide (LPS) from *Escherichia coli* (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) using a MicroSprayer® aerosolizer (PennyCentury Inc., Glenside, PA, USA).

**SPIO nanoparticles and lung exposure**

SPIO nanoparticles used in this study were coated with 40,000 g/mol dextran and functionalized by the addition of 300 g/mol polyethylene glycol (PEG) chain (Micromod Partikeltechnologie GmbH, Rostock, Germany). They were previously characterized, and their in vitro biocompatibility to macrophage subsets was extensively assessed.

To assess the in vivo biological impact of intrapulmonary administration of SPIO nanoparticles on the polarization...
profile of AMs in LPS-induced COPD lung, animals were divided into four groups (n=6 for each group): G_{ctrl}, control mice intrapulmonary instilled with physiological saline solution (V =100 mL); G_{LPS}, lung inflammation-bearing mice intrapulmonary instilled with LPS as a COPD model; G_{SPIO}, control mice intrapulmonary instilled with iron oxide nanoparticles ([Fe] =4 mM, corresponding to 16 mmol of iron per kilogram; V =100 μL) using the MicroSprayer® aerosolizer 24 hours post-LPS challenge; G_{LPS-SPIO} mice instilled with LPS and with SPIO 24 hours post-LPS challenge.

Isolation of pulmonary macrophages

Mice were sacrificed by overdose of intraperitoneal pentobarbital injection, their tracheas cannulated, and lungs lavaged three times with 1 mL phosphate-buffered saline (PBS) containing 0.6 mM/L ethylenediaminetetraacetic acid (EDTA) at 24 hours post-SPIO instillation corresponding to 48 hours post-LPS challenge. The supernatant was directly stored at −80°C for cytokines analysis. Inflammatory cell infiltration was determined by pooling lavaged samples from each mouse and counting cells using a Scepter™ automated cell counter (Merck Millipore, Billerica, MA, USA).

Twenty thousand bronchoalveolar lavage (BAL) cells/samples were cytospun and affixed to glass slides in −20°C methanol for 3 minutes. Cells were stained with Wright-Giemsa and differentially classified on the basis of nuclear morphology as neutrophils, macrophages, or lymphocytes. As the volume of BAL fluid (BALF) lavaged from each mouse varies between animals and groups, BAL data were expressed as cells/mL BALF.

Assessment of cytokine levels

Analyses of interleukins (ILs) and chemokines were performed on the BALF supernatants obtained from the different treatment groups. The levels of IL-12 and CXCL-10 (chemokine [C-X-C motif] ligand 10) as markers of M1-polarized macrophages and the levels of IL-4 and CCL-22 (chemokine [C-C motif] ligand 22) as markers of M2-polarized macrophages were quantified by an enzyme-linked immunosorbent assay (ELISA) as per the manufacturer’s protocol (R&D Systems, Abingdon, WI, USA). The cDNA was then amplified by real-time quantitative TaqMan® PCR using an ABI Prism 7700 (both Applied Biosystems, CA, USA) sequence detection system. Glyceraldehyde 3-phosphate dehydrogenase was analyzed as an internal control. SYBR Green Master PCR mix (Applied Biosystems) was used to amplify nitric oxide synthase (NOS)-2, CXCL-10, and tumor necrosis factor (TNF) as markers of M1 macrophages, and CCL-17, CCL-22, arginase 1 (Arg1), and IL-10 primers (Integrated DNA Technologies, Leuven, Belgium) as markers of M2 macrophages. Primers for NOS-2 were 5′-CGCAGCTGGGCTGTAACAA-3′ and 5′-TGATGTTTGTCTCGACATCA-3′; for CXCL-10, 5′-GCTGCCGTCTTTCTGC-3′ and 5′-TCTCACTGCGCCCGTAC-3′; for TNF, 5′-CTTGACCCACGTCTGAC-3′ and 5′-TTGAGACCTGCGGTGG-3′; for CCL-17, 5′-TGCTTCTTGGGACTTTCTG-3′ and 5′-GATGGCCCCTTGAAGTATA-3′; for CCL-22, 5′-TCTTGTCTGTGGAATCAGA-3′ and 5′-GAGGGTACGGGATGTAGTCC-3′; for Arg1, 5′-GAATCTCTGATGGGGAACC-3′ and 5′-GAATCCTGTGATCCACTGGGAC-3′; and for IL-10, 5′-GAAGCATGGGCCAGAATCA-3′ and 5′-TGCTCCACTGCTTGTCTTT-3′. The gene expressions in SPIO, LPS, and LPS-SPIO mice were presented as a fold increase in transcript expression compared with control mice. The fold difference in mRNA (messenger RNA) expression between the different groups was determined using a software program developed by Applied Biosystems.

Flow cytometry analyses of BALF

BALF from another set of animals (n=3 for each) was seeded in cell culture flask to enable adherence of macrophages for 2 hours. Macrophages were then scraped, and flow cytometry analysis was performed to characterize the AM subpopulations based on their surface membrane receptors. Cells were stained with the following anti-mouse antibodies: fluorescein isothiocyanate (FITC)-labeled anti-cluster of differentiation 11b (CD11b), Alexa Fluor® (Life Technologies) 488-labeled anti-CD86, Alexa Fluor® 647-labeled anti-CD197, FITC-labeled anti-CD206 and RPE (R-phycocerythrin)-labeled anti-CD150 (AbD Serotec, Kidlington, UK) and analyzed (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's specifications and then stored at −80°C. RNA (ribonucleic acid) was then reverse-transcribed into complementary deoxyribonucleic acid (cDNA) using M-MLV reverse transcriptase (Promega Corporation, Madison, WI, USA). The cDNA was then amplified by real-time quantitative TaqMan® PCR using an ABI Prism 7700 (both Applied Biosystems, CA, USA) sequence detection system. Glyceraldehyde 3-phosphate dehydrogenase was analyzed as an internal control. SYBR Green Master PCR mix (Applied Biosystems) was used to amplify nitric oxide synthase (NOS)-2, CXCL-10, and tumor necrosis factor (TNF) as markers of M1 macrophages, and CCL-17, CCL-22, arginase 1 (Arg1), and IL-10 primers (Integrated DNA Technologies, Leuven, Belgium) as markers of M2 macrophages. Primers for NOS-2 were 5′-CGCAGCTGGGCTGTAACAA-3′ and 5′-TGATGTTTGTCTCGACATCA-3′; for CXCL-10, 5′-GCTGCCGTCTTTCTGC-3′ and 5′-TCTCACTGCGCCCGTAC-3′; for TNF, 5′-CTTGACCCACGTCTGAC-3′ and 5′-TTGAGACCTGCGGTGG-3′; for CCL-17, 5′-TGCTTCTTGGGACTTTCTG-3′ and 5′-GATGGCCCCTTGAAGTATA-3′; for CCL-22, 5′-TCTTGTCTGTGGAATCAGA-3′ and 5′-GAGGGTACGGGATGTAGTCC-3′; for Arg1, 5′-GAATCTCTGATGGGGAACC-3′ and 5′-GAATCCTGTGATCCACTGGGAC-3′; and for IL-10, 5′-GAAGCATGGGCCAGAATCA-3′ and 5′-TGCTCCACTGCTTGTCTTT-3′. The gene expressions in SPIO, LPS, and LPS-SPIO mice were presented as a fold increase in transcript expression compared with control mice. The fold difference in mRNA (messenger RNA) expression between the different groups was determined using a software program developed by Applied Biosystems.
with BD™ LSR II flow cytometer using DIVA (BD Biosciences, San Jose, CA, USA) software.

**Antibody-conjugated SPIO functionalization**

To specifically target one subpopulation of macrophages in the lungs of COPD mice, and enable their noninvasive tracking using noninvasive MRI, specific M1 and M2 antibody-conjugated SPIO nanoparticles were developed.

Thiolated CD86 or CD206 antibodies (R&D Systems) targeted to M1 and M2 macrophage subsets, respectively, were conjugated to maleimide-functionalized SPIO nanoparticles. Sulfo-SMCC (4-(N-Maleimidomethyl)cyclohexane-1-carboxylic acid 3-sulfo-N-hydroxysuccinimide ester) cross-linker was first added to SPIO nanoparticles with CLDNH₂ (aminated cross-linked dextran) surface to introduce maleimide groups as previously described.\(^{18}\) Briefly, sulfoo-SMCC solution (100 µL of 14.35 µM) in DMSO (dimethyl sulfoxide) was added to 5 mg of iron oxide nanoparticles in PBS-EDTA buffer under gentle shaking for 1 hour at room temperature. After incubation, the suspension was washed with PBS-EDTA buffer with PD (protein desalting)-10 size-exclusion columns to remove unreacted sulfoo-SMCC. Then, the antibody conjugation to iron oxide nanoparticles was accomplished by the addition of maleimide-functionalized particles to the sulfhydryl-labeled antibody and incubation under gentle shaking for 3 hours at room temperature. The functionalization was performed under optimized conditions (ie, pH and dilution) to ensure homogeneous functionalization. Remaining functional groups were blocked by the addition of 100 µL of 20 mM freshly prepared cysteine solution. Finally, the antibody-conjugated SPIO nanoparticles were purified on magnetic columns (MACS Separator; Miltenyi Biotec, Bergisch Gladbach, Germany).

**Quantification of conjugated antibodies and measurement of nanoparticle size**

The amount of CD86 or CD206 antibodies conjugated to SPIO nanoparticles was measured using a modified bicinchoninic acid (BCA) protein assay that involves the reduction of Cu²⁺ to Cu⁺ by proteins and the formation of a purple-blue copper-protein complex in alkaline environment as previously described.\(^{19}\) Briefly, the calibration curve was obtained by adding increasing amounts of the CD86 or CD206 antibodies (1.6–25.0 µg/mL) to aminated iron oxide nanoparticles at a constant iron concentration of 0.5 mg/mL. The antibody-conjugated nanoparticles were adjusted to the same iron concentration of 0.5 mg/mL and developed with BCA reagent (Thermo Fisher Scientific, Bremen, Germany) together with the calibration curve for 2 hours at 37°C. Absorbance of the reaction products was measured at λ=562 nm using a Sunrise™ (Tecan, Crailsheim, Germany) microplate reader.

After filtration of the probe through a 0.22 µm polysulfone syringe filter, the hydrodynamic size of the nanoparticles was measured before and after antibody conjugation using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK) at constant iron concentration of 0.2 mg/mL in PBS buffer.

**MRI relaxivity measurements**

The relaxivities (r₁, r₂, and r₂*) of the different nanoparticles were measured at 25°C on tubes containing suspension of nanoparticles at different iron concentrations (0, 0.10, 0.15, 0.20, 0.40, 0.60, and 0.80 mM) using a 4.7T PharmaScan 47/16 Bruker magnet interfaced to ParaVision 5.1 software (Bruker Biospin GmbH, Rheinstetten, Germany). For the measurement of T₁ relaxation time, an IR-FISP (inversion-recovery fast imaging with steady state precession) sequence was used with repetition time (TR)/echo time (TE)=4/2 ms, and an increasing T₁ (inversion time) starting from T₁=100 ms with 60 echoes. For the measurement of T₂ relaxation time, an MSME (multi-spin multi-echo) sequence was used with a TR of 2,500 ms and increasing TEs starting from 12 ms, with 15 echoes of 12 ms echo spacing. For the measurement of T₂* relaxation time, an MGE (multi-gradient echo) sequence was used with a TR of 1,500 ms and increasing TEs starting from 4 ms, with 15 echoes of 4 ms echo spacing. T₁, T₂, and T₂* relaxation times were automatically calculated using the ParaVision® (Bruker Biospin GmbH) image analysis software. Relaxivities were then calculated as the slope of the linear regression generated from a plot of the measured relaxation rate (1/Tᵢ, where i=1, 2, or 2*) versus the concentration of the particles, ie, (1/Tᵢ)=(1/Tᵢ(0))+ ri[SPIO], where Ti denotes the relaxation times of a suspension containing the particles, and Ti(0) is the relaxation time of the solvent (water) without particles.

**Noninvasive detection using MRI**

To noninvasively detect M1 or M2 macrophage subpopulations targeted with either CD86- or CD206-conjugated SPIO nanoparticles and monitor their biodistribution in LPS-induced COPD model, a free-breathing imaging protocol using a radial ultra-short TE (UTE) sequence (TR/TE=100/0.4 ms, four averages, total acquisition time =5 min 21 s) with 100 µm × 100 µm pixel resolution and 1 mm axial slice thickness was used. This protocol enabled simultaneous detection of antibody-conjugated magnetic nanoparticles targeted to
macrophages and the visualization of inflammation progression in the lung. Pulmonary MRI protocol was performed on mice (n=10) before LPS induction (control group), 48 hours post-LPS challenge, and 2 hours post-intrapulmonary administration of either non-conjugated (LPS + SPIO), CD86-conjugated (LPS + CD86-SPIO), or CD206-conjugated (LPS + CD206-SPIO) SPIO nanoparticles. Based on preliminary studies (data not shown), 2 hours post-intrapulmonary administration of nanoparticles was found sufficient to enable specific targeting and therefore was chosen for MRI and investigation of the polarization profile of AMs.

Image analysis was performed as previously described. Briefly, the regions of interest were drawn around apparent vascular structures, and these regions were subtracted from the map to retain lung parenchyma. Threshold was chosen to include all apparent fluid signals in lung parenchyma. The number of hyperintensity pixels was averaged on a set of ten slices, with 0.5 mm inter-slices positioned at the same position in lung parenchyma for all animals.

Characterization of targeted macrophages using flow cytometry

Macrophages were obtained from mouse lungs (n=5) after MRI protocol at 2 hours post-antibody-conjugated SPIO nanoparticle administration. They were prepared for flow cytometry as per the protocol described elsewhere. Briefly, the dissected lungs were held in complete RPMI (Roswell Park Memorial Institute) medium supplemented with 25 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid). Lungs were minced in complete medium, and the filtrates were centrifuged (1,500 rpm for 5 minutes). The number of cells in the supernatant was determined, and then the solutions were passed through magnetic activated cell sorter (MACS) microbeads and through MACS LD or MS columns, as per the manufacturer’s protocol (Miltenyi Biotec). The eluted unbound and bound cell fractions were first separated, and after a repeat cell count, they were tested for different markers by flow cytometry. The cells were then washed, fixed, and permeabilized with Cytofix/Cytoperm™ (BD Biosciences). They were stained with either Alexa Fluor® 488-labeled anti-CD86 or FITC-labeled anti-CD206 anti-mouse antibodies and analyzed with the BD™ LSR II flow cytometer.

Lung immunohistochemistry and Prussian blue staining

Lungs (n=5) were removed and fixed overnight in 4% paraformaldehyde. They were then embedded in paraffin for histological analysis, and sets of four consecutive 5 µm thick sections were obtained. Immunohistochemistry was then performed using the following primary antibodies: F4/80 rat monoclonal immunoglobulin G (1:100), NOS-2 rabbit polyclonal antibody (1:1,000), and arginase goat polyclonal antibody (1:100) (Santa Cruz Biotechnology, Inc.). Respective mouse avidin biotin complex (ABC) staining systems were used as secondary antibodies according to the manufacturer’s protocol. Briefly, tissue sections were deparaffinized and incubated with primary antibodies diluted in blocking sera. Slides were then washed and incubated with biotinylated secondary antibodies followed by enzyme reaction with addition of peroxidase substrate. The sections were counterstained with hematoxylin, dehydrated in a series of alcohols and xylene solutions, mounted, and observed under a BX53 (Olympus Corporation, Tokyo, Japan) microscope.

To check for the presence of antibody-conjugated SPIO nanoparticles and their co-localization with macrophages, a Prussian blue staining protocol was followed. Sections were stained in a 1:1 solution of 20% aqueous hydrochloric acid and 10% aqueous solution of potassium ferrocyanide. They were then counterstained with neutral red, dehydrated with a series of alcohols, cleared in xylene, and observed after mounting.

Statistical analysis

Data presented as the mean standard deviation were analyzed by t-test using SPSS v 12.0 (SPSS Inc., Chicago, IL, USA) software. A P-value <0.05 was considered significant for all tests.

Results

Effect of SPIO and/or LPS intrapulmonary exposure on the polarization state of AMs

Intrapulmonary instillation of LPS (0.5 mg·kg⁻¹·V=100 µL) was found to induce significant pulmonary inflammatory responses related to alterations in lung capacity and mechanics as observed in COPD. Accordingly, the peak influx of total inflammatory cells was detected at 48 hours, and subsequent marked decline started from 72–96 hours post-LPS challenge (Figure 1A). The number of neutrophils, macrophages, lymphocytes, and total cells in BALF was quantified at 48 hours post-LPS instillation, corresponding to 24 hours post-SPIO nanoparticle instillation for the four different groups: control, SPIO, LPS, and LPS-SPIO (Figure 1B). The numbers of neutrophils (2.34 × 10⁶±0.31 × 10⁶) and macrophages (1.74 × 10⁶±0.19 × 10⁶) were found to considerably increase in the BALF compared with lymphocytes (0.15 × 10⁶±0.07 × 10⁶) (P<0.05).
To investigate the polarization state of AMs after lung administration of either SPIO, LPS, or both LPS and SPIO, the levels of IL-12 and CXCL-10 as markers of M1 macrophages and the levels of IL-4 and CCL-22 as markers of M2 macrophages was assessed using ELISA.

At 48-hours post-exposure, the levels of ILs (IL-12 and IL-4) and chemokines (CXCL-10 and CCL-22) were found to be higher than control group in both LPS and LPS-SPIO groups; however, only the level of CXCL-10 was found to statistically increase ($P<0.05$) (Figure 2).

To further evaluate the effect of LPS and/or SPIO instillation in the lung, the relative gene expression of NOS-2, CXCL-10, and TNF-α as markers of M1 macrophages and CCL-17, CCL-22, Arg1, and IL-10 as markers of M2 macrophages in SPIO, LPS, and LPS-SPIO mice compared with control mice was performed. A considerable increase in all gene markers was found 48 hours following LPS intrapulmonary exposition, with a 145-fold increase observed for CXCL-10, a 78-fold increase for TNF-α, a 28-fold increase for CCL-17, and a 12-fold increase for IL-10, compared with control group (Figure 3). However, a limited increase in gene expression was observed in the SPIO group, with a maximum of 10-fold increase observed for CXCL-10, and 1.8, 3.0, 3.3, and 4.4-fold increases observed for Arg1, IL-10, TNF-α, and CCL-17, respectively.

Remarkably, while LPS significantly increased the numbers of inflammatory cells, SPIO nanoparticles were found to cause only a minor increase in both macrophages and neutrophils 24 hours post-instillation compared with control group ($P<0.05$).
allowed to adhere in cell culture flask for 2 hours to obtain only adherent cells.

Adherent cells were found to be CD11b positive in all groups, indicating that macrophages were obtained. Following LPS exposure, macrophages exhibited an over-expression of both CD86 and CD206, with 41.9%±3.7% and 34.1%±3.1%, respectively, in the LPS group compared with 12.3%±2.6% and 22.1%±2.2%, respectively, in the control group (Figure 4). The percentage of cells expressing CD86 was significantly increased (P<0.05) with SPIO, LPS, and LPS-SPIO, and cells expressing CD206 were significantly increased with LPS and LPS-SPIO. In addition, intrapulmonary instillation of SPIO statistically increased (P<0.05) the expression of CD86 (28.7%±2.9% in the SPIO group compared with 12.3%±2.6% in the control group), while the increase in CD206 (28.2%±1.9% in the SPIO group compared with 22.1% in the control group) was not statistically significant (P>0.05). Conversely, CD197 and CD150 revealed a high overexpression in all the different groups, with no significant variation after treatment.

Physical characterization of antibody-conjugated SPIO nanoparticles

CD86- and CD206-conjugated SPIO nanoparticles were then developed to specifically target M1- and M2-macrophage subpopulations, respectively, in the lung of
the LPS-induced COPD model to enable their noninvasive imaging using MRI.

Measurement of the hydrodynamic size revealed that the mean nanoparticle diameter increased after conjugation of CD86 and CD206 antibodies to 133.7 nm and 123.0 nm, respectively, whereas the size of non-conjugated SPIO nanoparticles was 82.7 nm.

Quantification of protein concentration using BCA assay showed that the amount of bound antibody was 15 μg and 29 μg per mg of iron oxide for CD86- and CD206-conjugated SPIO nanoparticles, respectively.

Measurement of r1, r2, and r2* relaxation values at 4.7T exhibited very high r2 and r2* values (229.48±3.44 and 264.52±4.16 mM⁻¹·s⁻¹) for SPIO nanoparticles that slightly decreased after conjugation with either CD86 (201.48±5.89 and 234.24±6.16 mM⁻¹·s⁻¹ for r2 and r2*, respectively) or CD206 (209.84±7.51 and 229.97±6.27 mM⁻¹·s⁻¹ for r2 and r2*, respectively) antibodies. For all samples, r1 values were found negligible (0.06±0.01 mM⁻¹·s⁻¹).

Noninvasive targeting and imaging of AM subpopulations
Noninvasive MRI performed at 48 hours post-LPS intrapulmonary instillation using UTE sequence enabled successful detection of hyperintensity regions related to edema in the lung. These regions were homogenously distributed in the different lobes. Quantitatively, the number of hyperintensity regions per slice was found to increase to 3897±495 in 48 hours post–LPS group, compared with 1975±398 in control group (Figure 5).

Furthermore, the possibility of using a very short TE enabled obtaining enough MRI signal in lung parenchyma, which has always been limited by conventional MRI sequences. This protocol has offered the possibility of successful detection of void signal dots related to antibody-conjugated iron oxide nanoparticles in the lung. The number of hyperintensity pixels was therefore found to decrease significantly (P<0.05) following intrapulmonary administration of either CD86- or CD206-conjugated SPIO nanoparticles to 2910±356 and 2845±394, respectively. Interestingly, these antibody-conjugated magnetic nanoparticles were found to co-locate with the inflammatory regions in the lungs (red arrows in Figure 5), while non-conjugated SPIO nanoparticles were not found to confine to the inflammatory regions.

Characterization of polarization profile of targeted AMs
To confirm the MRI readouts and assess the polarization state of targeted AM subpopulations, flow cytometry and immunohistochemistry analysis following the MRI protocol were performed.

Flow cytometry analysis on targeted macrophage subpopulations sorted from total cellular extracts of mice lungs showed a statistically significant increase in the expression of CD86 (50.7%±5.4%) in the eluted bound cell fractions (ie, M1 targeted macrophages) of 48-hour post-LPS
Following intrapulmonary administration of either CD86- or CD206-SPIO nanoparticles, a high number of blue dots were detected using Perl’s staining (black arrows, Figure 7) and found to be co-localized with iNOS and Arg1 markers, indicating successful targeting of the different AM subpopulations, while no co-localization was observed following administration of non-conjugated SPIO nanoparticles. No significant variation in the expression levels of iNOS and Arg1 was observed following the instillation of the different SPIO nanoparticles.

Discussion
In this study, a noninvasive imaging protocol coupled with the use of biocompatible antibody-conjugated iron oxide nanoparticles was developed to enable specific targeting and imaging of a particular macrophage subset in COPD. Noninvasive tracking of a single-cell population in inflammatory diseases is required for both diagnostic purposes and therapeutic applications.22,23 To validate our approach,
Figure 7 Immunohistochemistry analysis of F4/80 (universal marker of macrophages), iNOS (marker for M1 macrophages), Arginase1 (marker for M2 macrophages), and Prussian blue (marker for iron oxide) staining in 48 hours post-LPS-induced COPD lung before and after intrapulmonary administration of either SPIO, CD86-SPIO, or CD206-SPIO nanoparticles.

Note: Final original magnification, ×400.

Abbreviations: COPD, chronic obstructive pulmonary disease; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; SPIO, superparamagnetic iron oxide; CD, cluster of differentiation.

the effect of intrapulmonary administration of iron oxide nanoparticles on the polarization profile of AMs was first investigated. Then, a specific biomarker for each macrophage subpopulation was selected for conjugation with biocompatible SPIO nanoparticles. This complex has enabled, for the first time, a noninvasive detection of a specific subpopulation of macrophages in the lung of LPS-induced COPD model using a free-breathing MRI protocol.

Extensively used in preclinical investigations, the intrapulmonary exposure of the bacterial endotoxin LPS triggers the production of inflammatory mediators, which results in enhanced macrophage phagocytic and cytotoxic activity and reproduces the pathophysiological features that resemble COPD.24–27 While the induction of lung inflammation in response to LPS is well documented, the inflammatory process has been shown to depend on various factors such as animal strain, route and dose of LPS exposition, and bacterial strain used (ie, *Escherichia coli* or *Pseudomonas aeruginosa*), which might affect its relevance as a model of COPD.28,29 Therefore, a full characterization of the pulmonary inflammatory process has to be performed under the experimental conditions used.

Similar to what has been reported in the different studies,29–31 the peak inflammatory process was observed at 48 hours post-LPS challenge, with neutrophils and macrophages forming more than 95% of total inflammatory cells in BALF. However, while LPS significantly increased the number of inflammatory cells, the intrapulmonary administration of PEGylated dextran-coated iron oxide nanoparticles ([Fe]=4 mM; V=100 µL) using the MicroSprayer® aerosolizer were found to only slightly increase macrophages and neutrophils at 24 hours post-administration, suggesting the safety of the SPIO nanoparticles used.

While different studies have reported the safety of different formulations of engineered iron oxide nanoparticles for biomedical applications,32 and some iron oxide nanoparticles have obtained US FDA approval as MRI contrast agents, there is still some discrepancy in the literature about the safety of these nanomaterials for pulmonary biomedical applications. Therefore, a long-term assessment of the chronic safety of iron oxide nanoparticles is required for safe and effective respiratory medical applications based on nanotechnology.

To investigate the polarization state of AMs after intrapulmonary instillation of either SPIO and/or LPS, cytokine-release measurement using ELISA, relative gene expression using RT-PCR, and surface membrane receptor expression using flow cytometry analysis were performed on the BALF of mice lungs. While LPS significantly increased
the levels of all M1 (ie, IL-12, NOS-2, CXCL-10, TNF-α, and CD86) and M2 (ie, IL-4, IL-10, CCL-17, CCL-22, Arg1, and CD206) biomarkers, the intrapulmonary instillation of PEGylated dextran-coated SPIO nanoparticles was found to slightly elevate the levels of CXCL-10 in ELISA, accompanied with an increase in its relative gene expression along with an overexpression of CD86, which is a marker of M1 polarization.

Significant elevations of IL-12, IL-4, CXCL-10, and CCL-22 were observed with both LPS and LPS-SPIO treatment \((P<0.05)\). SPIO induced significant elevations in CXCL-10 but not in other cytokines and ILs (Figure 2). Gene expression analyses also showed 10-fold elevations in CXCL-10 with SPIO, in contrast to either LPS or LPS-SPIO groups which showed expression levels of more than 100-fold increase. However, it has been observed that there was no decrease in the viability and biocompatibility of cells when treated with SPIO. As previously reported,\(^\text{35}\) although the levels of CXCL-10 or certain chemokines are elevated, iron oxide nanoparticles do not cause significant changes in the immune functions of cells.

The overexpression of both M1 and M2 markers following LPS lung administration was previously reported in several studies to orchestrate the pathophysiology of inflammatory process during COPD by activating either a pro-inflammatory M1 or immunomodulatory M2 profiles, depending on the environmental conditions of the inflammatory process.\(^\text{4,29,34}\) However, the increase in the expression of M1 markers (CXCL-10 and CD86) following SPIO nanoparticle administration may indicate that macrophages have recognized these nanoparticles as foreign, thus functioning to phagocytize them by activating their antigen-presenting function.

It must be reemphasized that although the gene expression of some markers (eg, CXCL-10, CCL-7, and TNF-α) was higher compared with control, the nanoparticles used in this study can be assumed biocompatible and safe for in vivo preclinical applications. However, complementary large-scale and long-term studies are required to conclusively establish this aspect for prospective clinical applications.

After assessing the biocompatibility of the PEGylated dextran-coated iron oxide nanoparticles and the effect of intrapulmonary administration of SPIO and/or LPS on the polarization profile of AM subpopulations, monoclonal antibodies raised against either CD86 or CD206 were conjugated to the iron oxide nanoparticles to specifically target M1 or M2 macrophage subpopulations, respectively, in the lung of an LPS-induced COPD model and enable their noninvasive detection using MRI.

Targeted magnetic nanoprobes have the potential to become highly selective imaging tools. The feasibility of successfully conjugating antibody molecules to SPIO nanoparticles was confirmed by the BCA assay, which revealed 15 \(\mu\)g of CD86 and 29 \(\mu\)g of CD206 antibodies per mg of SPIO nanoparticles, as well as the measurements of the hydrodynamic size, which indicated an increase in the nanoprobe size from 82.7 nm for non-conjugated to 133.7 and 123.0 nm for CD86 and CD206 antibody-conjugated SPIO nanoparticles, respectively. The size of administered nanoprobes to the lung is a key factor that regulates the delivery of therapeutics and contrast agents through the pulmonary route and particularly affects the rate of engulfment by AMs. Therefore, nanoparticles in the range of 100 nm were preferred for pulmonary administration in this study, as they should be small enough to pass through the conducting airways in the lung but not too small that they fail to deposit and are exhaled again.\(^\text{35}\)

On the other hand, magnetic nanoparticles with increased \(r_2\) or \(r_2^*\) transverse relaxivities are needed to enhance their contrast in MRI images and therefore their efficient detection, especially for pulmonary applications with very limited MRI signal in lung parenchyma.

The PEGylated dextran-coated iron oxide nanoparticles with an iron oxide crystallite diameter of 10–13 nm and a total size of \(-100\) nm were found to have very high \(r_2\) and \(r_2^*\) relaxivities (229.48±3.44 and 264.52±4.16 mM\(^{-1}\)-s\(^{-1}\)) for non-conjugated SPIO nanoparticles, which slightly decreased after conjugation with either CD86 (201.48±5.89 and 234.24±6.16 mM\(^{-1}\)-s\(^{-1}\)) or CD206 (209.84±7.51 and 229.97±6.27 mM\(^{-1}\)-s\(^{-1}\)) for \(r_2\) and \(r_2^*\), respectively) antibodies. This chemical composition was reported to facilitate the exchange and diffusion of water molecules to the magnetic core of the magnetic nanoparticles.\(^\text{36,37}\) and these relaxivity values were found to be much higher than the clinically approved MRI contrast agents Feridex\(^\text{®}\) IV (Berlex Laboratories, Wayne, NJ, USA) and Resovist\(^\text{®}\) (Bayer Healthcare, Berlin, Germany) that were reported in the literature.\(^\text{38,39}\)

A free-breathing MRI protocol was then optimized to enable the simultaneous visualization of inflammation progression in the lung of LPS-induced COPD animal model and the noninvasive detection of M1 or M2 macrophage subpopulations, which were specifically targeted with the developed antibody-conjugated nanoprobes.

The possibility of inflammation detection in the lung following LPS exposition using a free-breathing MRI protocol was first introduced by Beckmann et al\(^\text{40}\) using a gradient echo sequence with a high number of excitations (ie, \(N_{\text{ex}} = 60\)).\(^\text{40}\)
The absence of a lung parenchymal signal in combination with a background free of artifacts has provided a high contrast-to-noise ratio for the detection of signals in response to LPS challenge. However, this protocol was limited for the detection of iron oxide-based nanoparticles, which induce a negative contrast in MRI images.

With the recent introduction of UTE pulse sequence in MRI\(^1\) and its validation as an approach particularly valuable in imaging lung tissue, which is characterized by very short T2* relaxation time,\(^4\) Conti et al\(^2\) showed that UTE sequence is able to better detect inflammatory regions in lung parenchyma which were, in some slices, undetectable by standard gradient echo sequence.

By using a very short TE (ie, \(\text{TE} = 0.4\) ms), UTE sequence enabled enough MRI signal in the parenchyma of lung and therefore offers the possibility of sensitively detecting magnetic nanoparticles in the lung. In the current study, following CD86- and CD206-conjugated iron oxide nanoparticles, void signal dots related to targeting either M1 or M2 macrophages were successfully detected in the lung of COPD model (ie, 25% decrease in hyperintensity pixels) and were found to co-localize with the inflammatory regions induced by LPS challenge.

The successful recruitment of antibody-conjugated SPIO nanoparticles by macrophage subpopulations in the lung following their intrapulmonary instillation was thus confirmed using flow cytometry and immunohistochemistry analyses, which were also performed to characterize the polarization profile of targeted AMs.

Following magnetic sorting of total cellular extracts of mice lungs, an overexpression of CD86 and CD206 was detected in the eluted bound fractions of CD86- and CD206-conjugated SPIO nanoparticles, respectively, confirming the selective targeting of M1 and M2 macrophage subpopulations, respectively. Besides, no variation in the expression of CD86 and CD206 was observed in the other groups.

In accordance with these observations, a co-localization of either CD86- or CD206-conjugated iron oxide nanoparticles revealed through positive Prussian blue staining was detected with either iNOS M1-specific or Arg1 M2-specific marker in LPS-induced lung using immunohistochemistry analysis. Furthermore, no variation in the expression levels of iNOS and Arg1, which were highly expressed following LPS pulmonary challenge, was observed following the administration of the macrophage-targeted nanoparticles.

Although it becomes evident that AMs are extremely versatile cells and can switch their polarization profile depending on the environmental conditions, a balanced proportion of macrophage subpopulations was found to predominate even though a continuum switch in their polarization might occur. Accordingly, this study provides preliminary evidence for the presence of a balanced number of M1 and M2 macrophages at early stages of LPS-induced inflammation, which we believe may continuously change their polarization state during the time course of inflammation. However, further confirmatory studies are needed to conclusively establish this phenomenon.

**Conclusion**

In conclusion, AM polarization was extensively characterized after LPS and/or SPIO intrapulmonary administration. Specific biomarkers targeted to either M1 or M2 macrophage subpopulations were identified. Biocompatible antibody-conjugated iron oxide nanoparticles have thus been reported in the current paper as a novel approach to specifically target one subpopulation of macrophages in the lung of a COPD animal model and enable their noninvasive tracking using a free-breathing MRI protocol. Flow cytometry and immunohistochemistry analysis confirmed MRI readouts and suggested a balance in the number of M1 and M2 macrophages during the inflammatory process and after pulmonary administration of the nanoprobes that can serve as diagnostic and therapeutic agents.

**Acknowledgments**

This work was supported by NPST Program, King Saud University; Project Number 11-MED1773. We thank Cordula Gruttner from Micromod Partikeltechnologie GmbH for help in nanoparticle conjugation and Emmanuelle Canet-Soulas from the University of Lyon for helpful discussion.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


